Steady improvement in execution to drive earnings growth
A better product mix and an increasing share of exports should add glitter to Sky Gold & Diamonds
The sector is showing a sequential improvement in operational performance
Aarti Industries well positioned to start reaping the benefits of a massive capex cycle, which is underway.
Fundamentals are improving for Syngene while the stock is in a consolidation phase
Power Grid’s improved operating performance and the company’s strategy to aggressively deploy growth capital, following a revival in the domestic T&D capex cycle, are among the factors that make it an attractive bet
MapmyIndia has seen consistent margin expansion and has the potential to go higher because of its cost structure
With the emerging threat of the new COVID variant, JN.1, equity markets are likely to be volatile in the coming days. Defensive stocks like Divi’s Lab will merit attention
Emerging growth opportunities are a big positive for Navin Fluorine, whose valuation premium is likely to sustain
The company’s focus on profitability and the strong growth in its order book should support the stock
Even though pricing headwinds remain in the generic portfolio, we believe new growth opportunities can reinvent the earnings trajectory for the company.
Given the growth potential, aggressive investments, and supportive balance sheet, SRF is poised to counter cyclical headwinds better
The stock is expected to benefit from improving revenue visibility, better margins, and strong order inflows
With strong earnings visibility and valuations, GRSE offers a decent risk-reward proposition
A pick-up in the core business, contribution from emerging segments, and attractive valuations along with strong dividend yield should support the stock
Order book provides visibility to revenue and earnings growth; return of private capex to boost stock sentiment
Medium-term prospects look good for this company which has a vertically integrated business model and limited sourcing risk
The luggage company is set to benefit from a surge in travel and a shift in consumer preference towards branded products
The pharma company has a strong regulatory compliance record, expanding complex injectables capabilities, and a supportive balance sheet
Market factored in concerns: stock presents a decent risk-to-reward ratio
Strong outlook, attractive valuations make it a worthy bet for investors
Improving execution and margins to support earnings
Cigarette business is the key as it's one of the largest contributors to ITC’s profitability and cash flows
Stock trading at close to long-term support levels
A strong bet in a volatile market; monetisation of renewable assets to unlock value for NTPC